Results of imaging studies in involved groups of patients.

<p>NS- neck scan, US- ultrasound, WBS- ¹³¹I—whole body scan, CT- computed tomography, PET- positron emission tomography with ¹⁸ F-FDG, rhTSH/Tg–recombinant human thyrotropin-stimulated thyroglobulin, ND- not done, M- mediastinum, LN- lymph node</p><p>Results of imaging studies in involved groups of patients.</p

Recombinant human thyrotropin-stimulated thyroglobulin (rhTSH/Tg) sensitivity and specificity for cut-off level > 0.6 ng/ml.

<p>0-Group of patients with thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) < 2 ng/ml 1-Group of patients with thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) ≥ 2 ng/ml</p

Recombinant human thyrotropin-stimulated thyroglobulin (rhTSH/Tg) levels in groups of patients divided in accordance to thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) cut-off levels.

<p>N- number of patients</p><p>Recombinant human thyrotropin-stimulated thyroglobulin (rhTSH/Tg) levels in groups of patients divided in accordance to thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) cut-off levels.</p

Recombinant human thyrotropin-stimulated thyroglobulin (rhTSH/Tg) and thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) in the same patients in three groups: Group 1- THW/Tg < 2ng/ml; Group 2-THW/Tg ≥ 2ng/ml and < 10ng/ml; Group 3- THW/Tg ≥ 10 ng/ml.

<p>Recombinant human thyrotropin-stimulated thyroglobulin (rhTSH/Tg) and thyroid hormone withdrawal-stimulated thyroglobulin (THW/Tg) in the same patients in three groups: Group 1- THW/Tg < 2ng/ml; Group 2-THW/Tg ≥ 2ng/ml and < 10ng/ml; Group 3- THW/Tg ≥ 10 ng/ml.</p

Genotyping results according to tumor size (PTMiC or PTMaC) and diagnostic method (S, Seq; A, ASA-PCR; q, qPCR).

<p>Genotyping results according to tumor size (PTMiC or PTMaC) and diagnostic method (S, Seq; A, ASA-PCR; q, qPCR).</p

Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications - Fig 1

<p><b>Sequencing chromatograms representing three different types of results:</b> a) mutation <i>BRAF</i> c.1799T>A (p.V600E) present; b) ambiguous result; c) wild-type.</p

Genotyping results depending on the diagnostic method used (S, Seq; A, ASA-PCR; q, qPCR) in the entire cohort of 399 cases.

<p>Genotyping results depending on the diagnostic method used (S, Seq; A, ASA-PCR; q, qPCR) in the entire cohort of 399 cases.</p

<i>BRAF</i> c.1799T>A (p.V600E) mutation genotyping results using the ASA-PCR method visualized by MultiNA chip electrophoresis (Shimadzu, Japan).

<p>X1, molecular weight marker; A1, no template control; A2, negative control (sample without the BRAF p.V600E mutation; WT); A3, negative control sample without mutation (K-); A4, control sample with BRAF p.V600E mutation (K+); A5–A7 and C1, tested samples. 224pz, reaction control band; 126pz, band indicating the presence of the p.V600E mutation.</p

PPV, NPV and PVE according to the different risk stratification systems.

<p>PPV, NPV and PVE according to the different risk stratification systems.</p

Clinical outcome at the end of follow-up according to the ATA, ETA and DRS systems.

<p>Clinical outcome at the end of follow-up according to the ATA, ETA and DRS systems.</p